RESUMEN
Malaria is a tropical disease with significant morbidity and mortality burden caused by Plasmodium species in Africa, the Middle East, Asia, and South America. Pathogenic Plasmodium species have lately become increasingly resistant to approved chemotherapeutics and combination therapies. Therefore, there is an emergent need for identifying new druggable targets and novel chemical classes against the parasite. Falcipains, cysteine proteases required for heme metabolism in the erythrocytic stage, have emerged as promising drug targets against Plasmodium species that infect humans. This perspective discusses the biology, biochemistry, structural features, and genetics of falcipains. The efforts to identify selective or dual inhibitors and their structure-activity relationships are reviewed to give a perspective on the design of novel compounds targeting falcipains for antimalarial activity evaluating reasons for hits and misses for this important target.
Asunto(s)
Antimaláricos , Plasmodium , Humanos , Antimaláricos/química , Plasmodium falciparum , Inhibidores de Cisteína Proteinasa/farmacología , Inhibidores de Cisteína Proteinasa/química , Relación Estructura-ActividadRESUMEN
The pandemic situation of COVID-19 has caused global alarm in health care, devastating loss of lives, strangled economy, and paralysis of normal livelihood. The high inter-individual transmission rate created havoc in the global community. Although tremendous efforts are pitching in from across the globe to understand this disease, the clinical features seemed to have a wide range including fever, cough, and fatigue are the prominent features. Congestion, rhinorrhea, sore throat, and diarrhea are other less common features observed. The challenge of this disease lies in the difficulty in maneuvering the clinical course causing severe complications. One of the major causative factors for multi-organ failure in patients with severe COVID-19 complications is systemic vasculitis and cytokine-mediated coagulation disorders. Hence, effective markers trailing the disease severity and disease prognosis are urgently required for prompt medical treatment. In this review article, we have emphasized currently identified inflammatory, hematological, immunological, and biochemical biomarkers of COVID-19. We also discussed currently available biosensors for the detection of COVID-19-associated biomarkers & risk factors and the detection methods as well as their performances. These could be effective tools for rapid and more promising diagnoses in the current pandemic situation. Effective biomarkers and their rapid, scalable, & sensitive detection might be beneficial for the prevention of serious complications and the clinical management of the disease.
RESUMEN
Solid cancers are one of the leading causes of cancer related deaths, characterized by rapid growth of tumour, and local and distant metastases. Current advances on multimodality care have substantially improved local control and metastasis-free survival of patients by resection of primary tumour. The major concern in disease prognosis is the timely detection of resectable or metastatic tumour, thus reinforcing the need for identification of biomarkers for premalignant lesions of solid cancer. This ultimately improves the outcome for the patients. Therefore, the purpose of this review is to update the recent advancements on prognostic and diagnostic biomarkers to enhance early detection of common solid cancers including, breast, lung, colorectal, prostate and stomach cancer. We also provide an insight into Food and Drug Administration (FDA)-approved solid cancers biomarkers; various conventional techniques used for detection of prognostic and diagnostic biomarkers and discuss approaches to turn challenges in this field into opportunities.
Asunto(s)
Biomarcadores de Tumor , Neoplasias/diagnóstico , Humanos , PronósticoRESUMEN
Discovery of robust, selective and specific biomarkers are important for early diagnosis and monitor progression of human diseases. Eye being a common target for several human diseases, vision impediment and complications are often associated with systemic and ocular diseases. Tears are bodily fluids that are closest to eye and are rich in protein content and other metabolites. As a biomarker repository, it advantages over other bodily fluids due to the ability to collect it non-invasively. In this review, we highlight some recent advancements in identification of tear-based protein biomarkers like lacryglobin and cystatin SA for cancer; interleukin-6 and immunoglobulin-A antibody for COVID-19; tau, amyloid-ß-42 and lysozyme-C for Alzheimer's disease; peroxiredoxin-6 and α-synuclein for Parkinson's disease; kallikrein, angiotensin converting enzyme and lipocalin-1 for glaucoma; lactotransferrin and lipophilin-A for diabetic retinopathy and zinc-alpha-2 glycoprotein-1, prolactin and calcium binding protein-A4 for eye thyroid disease. We also discussed identification of tear based non-protein biomarkers like lysophospholipids and acetylcarnitine for glaucoma, 8-hydroxy-2'-deoxyquanosine and malondialdehyde for thyroid eye disease. We elucidate technological advancement in developing tear-based biosensors for diagnosis and monitoring diseases such as diabetes, diabetic retinopathy and Alzheimer's disease. Altogether, the study of tears as potential biomarkers for early diagnosis of human diseases is promising.
Asunto(s)
Biomarcadores de Tumor/metabolismo , COVID-19 , Detección Precoz del Cáncer , Oftalmopatías , Enfermedades Neurodegenerativas , SARS-CoV-2/metabolismo , Lágrimas/metabolismo , COVID-19/diagnóstico , COVID-19/metabolismo , Oftalmopatías/diagnóstico , Oftalmopatías/metabolismo , Humanos , Enfermedades Neurodegenerativas/diagnóstico , Enfermedades Neurodegenerativas/metabolismoRESUMEN
Immunomodulation activity-guided fractionation of ethanol extract of Brugmansia suaveolens leaves was carried out to isolate a novel compound SUPH036-022A (1) by co-culturing the test fraction/compound activated PBMC with MCF7 and A549 cancer cell lines. Assessment of immune markers in PBMC, and analysis of apoptosis markers and cell cycle was carried out for cancer cells. The structure of the isolated compound was elucidated by spectral analysis. Compound 1 enhanced the secretion of immune markers, IL-2 and IFN-γ, from PBMC. Further, compound 1 treated PBMC increased cell death in MCF7 and A549 cell lines and induced ROS production and mitochondrial membrane perturbation, leading to apoptosis. Flow cytometry analysis revealed; compound 1 stimulated PBMC to cause a five-fold increase in cell cycle perturbations in the sub-G1 stage of cancer cells as compared to the negative control. The compound, in the absence of PBMC, only had a weak cytotoxic activity against these cell lines. Thus, compound 1 is a novel lead for immunomodulation-mediated anticancer activity.
Asunto(s)
Brugmansia/química , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Brugmansia/metabolismo , Puntos de Control del Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Humanos , Interferón gamma/metabolismo , Interleucina-2/metabolismo , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Extractos Vegetales/química , Hojas de la Planta/química , Hojas de la Planta/metabolismo , Especies Reactivas de Oxígeno/metabolismoRESUMEN
Falcipains (FPs), cysteine proteases in the malarial parasite, are emerging as the promising antimalarial drug targets. In order to identify novel FP inhibitors, we generated a pharmacophore derived from the reported co-crystal structures of inhibitors of Plasmodium falciparum Falcipain-3 to screen the ZINC library. Further, the filters were applied for dock score, drug-like characters, and clustering of similar structures. Sixteen molecules were purchased and subject to in vitro enzyme (FP-2 and FP-3) inhibition assays. Two compounds showed in vitro inhibition of FP-2 and FP-3 at low µM concentration. The selectivity of the inhibitors can be explained based on the predicted interactions of the molecule in the active site. Further, the inhibitors were evaluated in a functional assay and were found to induce morphological changes in line with their mode of action arresting Plasmodium development. Compound 15 was most potent inhibitor identified in this study.
Asunto(s)
Antimaláricos/farmacología , Cisteína Endopeptidasas/metabolismo , Inhibidores Enzimáticos/farmacología , Plasmodium falciparum/efectos de los fármacos , Antimaláricos/química , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/química , Simulación del Acoplamiento Molecular , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Plasmodium falciparum/enzimología , Relación Estructura-ActividadRESUMEN
ROYLEA CINEREA (D.DON) BAILLON: Roylea cinerea (D.Don) Baillon family Lamiaceae is a shrub of the monotypic genus. Aerial parts of the plant are used traditionally in Indian sub-Himalayas and Nepal for the treatment of jaundice, skin diseases, malaria, diabetes, febrifuge and contusions. METHOD: This article reviews botanical description, phytochemistry, ethnomedicinal uses and pharmacological activities of R. cinerea to evaluate if the scientifically evaluated pharmacological profile of the plant can corroborate ethnomedicinal uses. A survey was conducted to document ethnomedicinal and folklore uses of the plant in five districts of Himachal Pradesh, India. RESULTS: Phytochemical studies of R. cinerea reveal the presence of glycosides, diterpenes, flavonoids, tannins, steroids, saponins and phenols. R. cinerea extracts. The compounds showed anticancer, antifungal, hepatoprotective, antiperiodic, antiprotozoal, antidiabetic and antioxidant activities on scientific evaluation. A diterpenoid from the plant, precalyone, exhibited antiproliferative activity against P-388 lymphocytic leukemia cell line. Cinereanoid D, a labdane diterpenoid that inhibits ATP binding of heat shock protein Hsp90, is a potential anticancer lead. Two compounds from aerial parts of the plant, 4-methoxybenzo[b]azet-2(1H)-one and 3ß-hydroxy-35-(cyclohexyl-5'-propan-7'-one)-33-ethyl-34-methylbacteriohop-16-ene, showed antidiabetic activity. Thus, the scientific reports confirm the ethnomedicinal use of this plant in diabetes, malaria and liver diseases. CONCLUSION: Roylea cinerea is a traditionally used medicinal plant from Western Himalayas. The pharmacological evaluation confirmed the ethnomedically claimed antidiabetic activity using scientifically accepted protocols and controls, although some of the studies require reconfirmation. The bioactivity-guided fractionation attributes the activity to 4-methoxybenzo[b]azet-2(1H)-one and 3ß-hydroxy-35-(cyclohexyl-5'-propan-7'-one)-33-ethyl-34-methylbacteriohop-16-ene. Further, cinereanoid D is a potential lead for targeting Hsp90 and its medicinal chemistry studies can lead to a potent anticancer compound. The plant extract also showed antimalarial and hepatoprotective activities. Some of the studies discussed in this review require reconfirmation, as the protocols lacked proper positive and negative controls. Thus, the review of the scientific reports on Roylea cinerea supports ethnomedicinal use as antidiabetic, antimalarial and hepatoprotective. Further studies to prove scientific basis for use in leucorrhea, skin diseases, inflammation and strengthening of claims for liver tonic are required.
Asunto(s)
Lamiaceae , Medicina Tradicional , Fitoterapia , Animales , Asia Occidental , Humanos , Lamiaceae/química , Fitoquímicos/análisis , Fitoquímicos/farmacología , Fitoquímicos/uso terapéutico , Preparaciones de Plantas/química , Preparaciones de Plantas/farmacología , Preparaciones de Plantas/uso terapéuticoRESUMEN
Cancer immunotherapies offer promise for cure of cancer with specificity and minimal toxicity. Recent developments in cancer immunology have led to the better understanding of role of immune regulatory mechanisms in cancer. There is rapid progress in this field in the last few years. Several clinical studies report the efficacy of immunotherapies for treating cancer. The immunology-based anticancer therapies have shown better safety profiles in clinic as compared to other chemotherapeutic agents, thus increasing interest in this area. This review summarizes recent advances in cancer immunology and discusses tumor microenvironment and immunology-based anticancer therapies, including vaccines and therapies targeting immune checkpoints.
Asunto(s)
Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Neoplasias/inmunología , Neoplasias/terapia , Animales , Vacunas contra el Cáncer/inmunología , Humanos , Inmunoterapia/métodos , Microambiente Tumoral/efectos de los fármacosRESUMEN
Sonic hedgehog (Shh) signaling influences neurogenesis and neural patterning during the development of central nervous system. Dysregulation of Shh signaling in brain leads to neurological disorders like autism spectrum disorder, depression, dementia, stroke, Parkinson's diseases, Huntington's disease, locomotor deficit, epilepsy, demyelinating disease, neuropathies as well as brain tumors. The synthesis, processing and transport of Shh ligand as well as the localization of its receptors and signal transduction in the central nervous system has been carefully reviewed. Further, we summarize the regulation of small molecule modulators of Shh pathway with potential in neurological disorders. In conclusion, further studies are warranted to demonstrate the potential of positive and negative regulators of the Shh pathway in neurological disorders.
Asunto(s)
Enfermedades del Sistema Nervioso , Transducción de Señal , Trastorno del Espectro Autista , Proteínas Hedgehog , Humanos , NeurogénesisRESUMEN
The present study was aimed to evaluate the effect of Urtica dioica (UD) extract against chronic unpredictable stress (CUS)-induced associative memory dysfunction and attempted to explore the possible mechanism. Male Swiss albino mice (25-30g) were divided into six groups, viz. group-I received 0.3% carboxymethyl cellulose and served as control (CTRL), group II was exposed to CUS (21days) and received vehicle (CUS), group III was subjected to CUS and received Hypericum perforatum extract (350mg/kg, p.o.) (CUS+HYP), group IV received Hypericum perforatum extract (350mg/kg, p.o.) (CTRL+HYP); group V was subjected to CUS and received UD extract (50mg/kg, p.o.) (CUS+UD), group VI received UD extract (50mg/kg, p.o.) (CTRL+UD). CUS significantly induced body weight loss (p<0.05) and associative memory impairment in step down task (p<0.05) as compared to control mice. CUS significantly downregulated Smo (p<0.05), Gli1 (p<0.01), cyclin D1 (p<0.05), BDNF (p<0.01), TrKB (p<0.01) and MAPK1 (p<0.01) mRNA expression in hippocampus as compared to control mice. CUS significantly increased the levels of TBARS (p<0.01) and nitric oxide (p<0.001), and decreased catalase (p<0.001) and total thiol (p<0.01) in plasma resulting in oxidative stress and inflammation. Chronic UD administration significantly reverted CUS mediated body weight loss (p<0.05) and cognitive impairment (p<0.05). UD administration significantly decreased the levels of TBARS (p<0.01) and nitric oxide (p<0.05), and increased the levels of catalase (p<0.01) and total thiol (p<0.05) in plasma. Chronic UD administration significantly upregulated hippocampal Smo (p<0.05), Gli1 (p<0.001), cyclin D1 (p<0.05), BDNF (p<0.05), TrKB (p<0.05) and MAPK1 (p<0.05) in stressed mice. Further, UD extract did not reverse cyclopamine induced downregulation of Gli1 and Ptch1 mRNA in hippocampal slices. UD modulated Smo-Gli1 pathway in the hippocampus as well as exerted anti-inflammatory and antioxidant effects. UD extract might prove to be effective for stress mediated neurological disorders.
Asunto(s)
Disfunción Cognitiva/tratamiento farmacológico , Hipocampo/patología , Extractos Vegetales/uso terapéutico , Hojas de la Planta/química , Receptor Smoothened/metabolismo , Estrés Psicológico/tratamiento farmacológico , Urtica dioica/química , Proteína con Dedos de Zinc GLI1/metabolismo , Animales , Cromatografía Líquida de Alta Presión , Enfermedad Crónica , Disfunción Cognitiva/complicaciones , Disfunción Cognitiva/patología , Disfunción Cognitiva/fisiopatología , Hipocampo/efectos de los fármacos , Hipocampo/fisiopatología , Masculino , Ratones , Plasticidad Neuronal/efectos de los fármacos , Nitrosación , Estrés Oxidativo/efectos de los fármacos , Fitoquímicos/análisis , Fitoquímicos/química , Extractos Vegetales/química , Extractos Vegetales/farmacología , Estándares de Referencia , Transducción de Señal/efectos de los fármacos , Estrés Psicológico/complicaciones , Estrés Psicológico/metabolismo , Estrés Psicológico/fisiopatología , Pérdida de Peso/efectos de los fármacosRESUMEN
The aim of the present investigation is to develop and statistically optimize the osmotically controlled asymmetric membrane capsules of solid dispersion of lycopene. Solid dispersions of lycopene with ß-cyclodextrin in different ratios were prepared using solvent evaporation method. Solubility studies showed that the solid dispersion with 1 : 5 (lycopene : ß-cyclodextrin) exhibited optimum solubility (56.25 mg/mL) for osmotic controlled delivery. Asymmetric membrane capsules (AMCs) were prepared on glass mold pins via dip coating method. Membrane characterization by scanning electron microscopy showed inner porous region and outer dense region. Central composite design response surface methodology was applied for the optimization of AMCs. The independent variables were ethyl cellulose (X1), glycerol (X2), and NaCl (X3) which were varied at different levels to analyze the effect on dependent variables (percentage of cumulative drug release (Y1) and correlation coefficient of drug release (Y2)). The effect of independent variables on the response was significantly influential. The F18 was selected as optimized formulation based on percentage of CDR (cumulative drug release) of 85.63% and correlation coefficient of 0.9994. The optimized formulation was subjected to analyze the effect of osmotic pressure and agitational intensity on percentage of CDR. The drug release was independent of agitational intensity but was dependent on osmotic pressure of dissolution medium.
Asunto(s)
Carotenoides/administración & dosificación , Sistemas de Liberación de Medicamentos , Carotenoides/química , Licopeno , Microscopía Electrónica de Rastreo , Ósmosis , SolubilidadRESUMEN
We have previously reported small-molecule inhibitors of Gli1-mediated transcription, an essential down-stream element of the Hh pathway. We created new derivatives of the previous compounds aiming to improve the druggable properties. The new compounds, amide conjugates of ketoprofen and indole, showed inhibitory activity and membrane permeability, while also improving the microsome stability. Among them, 33 and 42 inhibited Gli-luciferase reporter in C3H10T1/2 cells that were exogenously transfected with Gli1 with 2.6 µM and 1.6 µM of IC50, respectively, and in Rh30 cells that endogenously overexpress Gli1, and were selective to Gli1 over Gli2.
Asunto(s)
Amidas/química , Proteínas Hedgehog/metabolismo , Indoles/química , Indoles/síntesis química , Cetoprofeno/química , Factores de Transcripción/antagonistas & inhibidores , Amidas/síntesis química , Amidas/farmacología , Línea Celular , Permeabilidad de la Membrana Celular/efectos de los fármacos , Genes Reporteros , Humanos , Indoles/farmacología , Factores de Transcripción de Tipo Kruppel/antagonistas & inhibidores , Factores de Transcripción de Tipo Kruppel/metabolismo , Microsomas/metabolismo , Proteínas Nucleares/antagonistas & inhibidores , Proteínas Nucleares/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Transcripción Genética , Proteína con Dedos de Zinc GLI1 , Proteína Gli2 con Dedos de ZincRESUMEN
We report novel inhibitors of Gli1-mediated transcription as potential anticancer agents. Focused chemical libraries were designed and assessed for inhibition of functional cell-based Gli1-mediated transcription and selective toxicity toward cancer cells. The SAR was revealed, and the selectivity of the lead compounds' inhibition of Gli1-mediated transcription over that of Gli2 was determined. Compound 63 (NMDA298-1), which inhibited Gli1-mediated transcription in C3H10T1/2 cells with an IC(50) of 6.9 muM, showed 3-fold selectivity for inhibiting transcription mediated by Gli1 over that by Gli2. Cell-viability assays were performed to evaluate the chemical library in a normal cell line and a panel of cancer cell lines with or without up-regulated expression of the Gli1 gene. These compounds decreased the viability of several cancer cell lines but were less active in the noncancerous BJ-hTERT cells.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Neoplasias/patología , Proteínas Oncogénicas/metabolismo , Transactivadores/metabolismo , Transcripción Genética/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Genes Reporteros , Humanos , Concentración 50 Inhibidora , Proteínas Oncogénicas/genética , Pirazoles/química , Relación Estructura-Actividad , Transactivadores/genética , Tiramina/química , Proteína con Dedos de Zinc GLI1Asunto(s)
Antineoplásicos/farmacología , Proteínas Hedgehog/metabolismo , Transducción de Señal/efectos de los fármacos , Factores de Transcripción/metabolismo , Descubrimiento de Drogas , Proteínas Hedgehog/genética , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/etiología , Factores de Transcripción/genética , Proteína con Dedos de Zinc GLI1RESUMEN
This report describes the first small-molecule antagonists that specifically target the ligand-binding pocket of PDZ domains of NHERF1 multi-functional adaptor protein. Comparison of the peptide sequence homology between the native ligand of NHERF1 PDZ domains and an indole-based non-peptide chemical scaffold allowed the design of a small-molecule antagonist of NHERF1 PDZ domains.
Asunto(s)
Diseño de Fármacos , Indoles/síntesis química , Indoles/farmacología , Dominios PDZ/efectos de los fármacos , Fosfoproteínas/antagonistas & inhibidores , Intercambiadores de Sodio-Hidrógeno/antagonistas & inhibidores , Humanos , Indoles/química , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Relación Estructura-ActividadRESUMEN
We designed and synthesized a series of indole-2-amide-based compounds that antagonize interaction between the Dishevelled (Dvl) PDZ domain and a peptide derived from the natural PDZ ligand Frizzled-7 (Fz7). These compounds inhibit Tcf-mediated transcription activated by exogenous Dvl via the biochemical antagonism. We confirmed tumor cell-selective activation of caspases by these compounds.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/antagonistas & inhibidores , Amidas/síntesis química , Amidas/farmacología , Indoles/síntesis química , Indoles/farmacología , Modelos Moleculares , Fosfoproteínas/antagonistas & inhibidores , Factores de Transcripción TCF/metabolismo , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Amidas/química , Apoptosis/efectos de los fármacos , Técnicas Químicas Combinatorias , Proteínas Dishevelled , Humanos , Indoles/química , Estructura Molecular , Dominios PDZ/efectos de los fármacos , Fosfoproteínas/metabolismo , Relación Estructura-Actividad , Factores de Transcripción TCF/efectos de los fármacos , Transcripción Genética/efectos de los fármacos , Proteínas Wnt/fisiologíaRESUMEN
Dipeptidyl peptidase IV (DPP-IV) is a valid drug target for type-2 diabetes and DPP-IV inhibitors have been proven to efficiently improve glucose tolerance. In our study, 3D pharmacophore models were generated using a training set of 22 DPP-IV inhibitors. The best model consisted of important chemical features and mapped well into the active site of DPP-IV. The model gave high correlation coefficients of 0.97 and 0.84 for the training set and the test set, respectively, showing its good predictive ability for biological activity. Furthermore, the pharmacophore model demonstrated the capability to retrieve inhibitors from database with a high enrichment factor of 42.58. All results suggest that the model provides a useful tool for designing novel DPP-IV inhibitors.
Asunto(s)
Inhibidores de la Dipeptidil-Peptidasa IV/química , Inhibidores de la Dipeptidil-Peptidasa IV/farmacología , Modelos Moleculares , Sitios de Unión , Dipeptidil Peptidasa 4/química , Dipeptidil Peptidasa 4/metabolismo , Humanos , Concentración 50 Inhibidora , Estructura MolecularRESUMEN
Type 2 diabetes has rapidly reached an epidemic proportion becoming a major threat to global public health. PPAR agonists have emerged as a leading class of oral antidiabetic drugs. We report a structure biology analysis of novel indole-based PPAR agonists to explain the structure-activity relationships and present a critical analysis of reasons for change in selectivity with change in the orientation of the same scaffolds. The results would be helpful in designing novel PPAR agonists.
Asunto(s)
Indoles/química , Receptores Activados del Proliferador del Peroxisoma/agonistas , Receptores Activados del Proliferador del Peroxisoma/química , Acetatos/química , Alquilación , Sitios de Unión , Cristalografía por Rayos X , Humanos , Técnicas In Vitro , Indoles/síntesis química , Indoles/farmacología , Ligandos , Modelos Moleculares , Estructura Molecular , Naftalenos/síntesis química , Naftalenos/química , Naftalenos/farmacología , Receptores Activados del Proliferador del Peroxisoma/genética , Propionatos/química , Relación Estructura-Actividad , Termodinámica , Activación Transcripcional/efectos de los fármacosRESUMEN
The concise synthesis and structure-activity relationship (SAR) studies of 3-aroylindoles were carried out in an effort to improve the potency and solubility of anticancer drug candidate BPR0L075 (8) by exploring structure modifications through three regimens: substitution of the B ring, at the N1 position, and of the 3-carbonyl linker. The SAR information revealed that the methoxy group of the B ring could be replaced with an electron-donating group such as methyl (in compound 9) or N,N-dimethylamino (in compound 13) while retaining both strong cytotoxic and antitubulin activities. The introduction of amide (compounds 30-33) and carbamate (compounds 34-37) functionalities at the N1 position of 8 gave analogues with potent antiproliferative activities. The cytotoxic potency of 8 was improved by replacing the carbonyl group with sulfide (compound 41) or oxygen (compound 43), indicating that the carbonyl moiety is important but not essential. The N,N-dimethylamino derivative 13 not only displayed potent cytotoxicity and antitubulin activity, but also showed a markedly improved physicochemical profile relative to the parent compound.
Asunto(s)
Antimitóticos/farmacología , Antineoplásicos/farmacología , Indoles/farmacología , Moduladores de Tubulina/farmacología , Animales , Antimitóticos/síntesis química , Antimitóticos/química , Antineoplásicos/síntesis química , Antineoplásicos/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Técnicas In Vitro , Indoles/síntesis química , Indoles/química , Masculino , Estructura Molecular , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Relación Estructura-Actividad , Tubulina (Proteína)/efectos de los fármacos , Moduladores de Tubulina/síntesis química , Moduladores de Tubulina/química , Células Tumorales CultivadasRESUMEN
Severe acute respiratory syndrome coronavirus (SARS-CoV) main protease (M(pro)), a protein required for the maturation of SARS-CoV, is vital for its life cycle, making it an attractive target for structure-based drug design of anti-SARS drugs. The structure-based virtual screening of a chemical database containing 58,855 compounds followed by the testing of potential compounds for SARS-CoV M(pro) inhibition leads to two hit compounds. The core structures of these two hits, defined by the docking study, are used for further analogue search. Twenty-one analogues derived from these two hits exhibited IC50 values below 50 microM, with the most potent one showing 0.3 microM. Furthermore, the complex structures of two potent inhibitors with SARS-CoV M(pro) were solved by X-ray crystallography. They bind to the protein in a distinct manner compared to all published SARS-CoV M(pro) complex structures. They inhibit SARS-CoV M(pro) activity via intensive H-bond network and hydrophobic interactions, without the formation of a covalent bond. Interestingly, the most potent inhibitor induces protein conformational changes, and the inhibition mechanisms, particularly the disruption of catalytic dyad (His41 and Cys145), are elaborated.